Trial Profile
Investigation of pathways regulating early antiangiogenic response to bevacizumab given prior to neoadjuvant breast cancer chemotherapy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2010
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- 08 Jun 2010 Thrity-one patients have been recruited to date, according to information reported at ASCO 2010.
- 08 Jun 2010 New trial record